Brevilin A is a strong impetus for the development of selective JAK-STAT inhibitors and therapeutic drugs in order to improve survival of patients with hyperactivated JAKs and STATs. Brevilin A shows antigiardial activity (IC50 = 16.1 μM) and is similarly active in vitro against Entamoeba histolytica (IC50 between 4.5 and 9 μM) and against Plasmodium falciparum (IC50 = 9.42 μM).
1. Tirandamycin A and echinomycin A have anti-amoebic properties, they inhibit the in vitro growth of a E. histolytica laboratory strain (HM-1:IMSS) and a clinical isolate (Colombia, Col) at 30- to 60- uM concentrations.
2. Tirandamycin A and streptolydigin possess potent antibacterial activity particularly against anaerobes, have been shown to inhibit bacterial RNA polymerase.